Investigation Report on China Sertraline Market, 2010-2019
According to WHO, depression, an affective mental disorder, is quite common with an incidence of 3-5%. Currently, the number of depression patients has exceeded 90 million in China and still keeps increasing. It is expected that by 2020, depression will become the second biggest threat to human health.
Developed by Pfizer, Inc. in the early 1990s, sertraline (sertraline dydrochloride) has entered many countries like the US, European countries and Japan to treat dysthymi and has brought in an annual sales value of over 1 billion all over the world. As the newest product of selective serotonin reuptake inhibitor (SSRI), sertraline can help improve organism ability, reduce symptoms of depression like distress and alleviate persistent fatigue and anxiety. As one of the three SSRI drugs with certain efficacy (the other two being fluoxetine and paroxetine), sertraline has been widely used for the treatment of depressive disorder and obsessive-compulsive disorder.
According to CRI’s market survey, sertraline keeps growing with annual sales value rising from CNY 20 million in 2005 to CNY 148 million in 2014 and CAGR during this period reaching 23.50% after it entered China in 1996. Pfizer, Inc., Zhejiang Jingxin Pharmaceutical Co., Ltd, Tianjin Huajin Pharmaceutical Factory, Guangdong P.D. Pharmaceutical Co., Ltd and Chengdu Leer Pharmaceutical Co., Ltd occupy the majority of the Chinese market, among which Pfizer, Inc. had the largest market share of about 83% for sales value in 2014.
With the increased mental pressure brought about by economic development and lifestyle change, the number of depression patients keeps growing too. Therefore, the market size of sertraline is expected to expand in the next few years in China.
Readers can get at least the following information from this report:
market size of sertraline in China
competitive landscape of sertraline in Chinese market
price of sertraline made by different enterprises in China
market outlook of sertraline in China
suggests the following groups of people purchase this report:
manufacturers of antidepressant
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service